Acadia Pharmaceuticals (ACAD) Current Assets (2010 - 2026)

Acadia Pharmaceuticals has reported Current Assets for 17 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 25.84% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 25.84% YoY), and the FY2025 full-year result was $1.1 billion, up 13.19% from the prior year.
• Current Assets for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Current Assets was $1.1 billion in Q1 2026, with the low at $492.6 million in Q2 2023.
• Average Current Assets over 5 years is $730.1 million, with a median of $675.3 million recorded in 2024.
• Year-over-year, Current Assets dropped 19.55% in 2022 and soared 57.92% in 2024.
• Tracing ACAD's Current Assets over 5 years: stood at $507.9 million in 2022, then gained by 21.3% to $616.1 million in 2023, then surged by 52.29% to $938.3 million in 2024, then climbed by 13.19% to $1.1 billion in 2025, then grew by 3.19% to $1.1 billion in 2026.
• The last three Current Assets figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison